Get started
Author

Francis Kiweewa

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
2022 · Nicholas I Paton, Joseph Musaazi, et al. · The Lancet HIV · 137
PDF
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
2022 · Thomas L. Holland, Adit A. Ginde, et al. · The Lancet Respiratory Medicine · 123
PDF
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
2017 · Nicholas I Paton, Nicholas I Paton, et al. · The Lancet HIV · 80
PDF
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries
2020 · Trevor A Crowell, Brook Danboise, et al. · Clinical Infectious Diseases · 53
PDF
Factors associated with sexually transmitted infections among care-seeking adults in the African Cohort Study
2021 · for the AFRICOS Study Group, Michael Semwogerere, et al. · BMC Public Health · 45
PDF
Dissecting Drivers of Immune Activation in Chronic HIV-1 Infection
2021 · Hendrik Streeck, Alvino Maestri, et al. · EBioMedicine · 37
PDF
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group*, Christina Barkauskas, et al. · Annals of Internal Medicine · 31
PDF
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
2023 · Betty Mwesigwa, Katherine V Houser, et al. · The Lancet Infectious Diseases · 27
Clinical factors and outcomes associated with immune non-response among virally suppressed adults with HIV from Africa and the United States
2022 · Adi Noiman, Allahna Esber, et al. · Scientific Reports · 26
PDF
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
2023 · Gustavo H Dayan, Nadine Rouphael, et al. · The Lancet Respiratory Medicine · 25
PDF
Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African Cohort Study
2020 · the AFRICOS Study Group, Emmanuel Bahemana, et al. · AIDS Research and Therapy · 25
PDF
Predictors and Barriers to Condom Use in the African Cohort Study
2020 · Tope Analogbei, Nicole Dear, et al. · AIDS Patient Care and STDs · 19
Frequency and Predictors of HIV-Related Cognitive Impairment in East Africa: The Africa Cohort Study (AFRICOS)
2020 · Benedetta Milanini, Isabel Allen, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 17
Monocyte activation, HIV, and cognitive performance in East Africa
2019 · L. Arnoldo Muñoz-Nevárez, Brandon M. Imp, et al. · Journal of NeuroVirology · 17
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 15
PDF
Brief Report: Increased Inflammation and Liver Disease in HIV/HBV-Coinfected Individuals
2021 · Nathanial K. Copeland, Michael A. Eller, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 11
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial
2018 · Jennifer A Thompson, Cissy Kityo, et al. · Clinical Infectious Diseases · 11
PDF
In-vitro Immunomodulatory activity of Azadirachta indica A.Juss. Ethanol: water mixture against HIV associated chronic CD4+ T-cell activation/ exhaustion
2021 · Omalla A. Olwenyi, Bannet Asingura, et al. · BMC Complementary Medicine and Therapies · 8
PDF
Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda
2020 · Karen A. Martins, Rodgers R. Ayebare, et al. · Health Security · 7
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 6
PDF
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
2023 · Tomas O Jensen, Greg A Grandits, et al. · The Journal of Infectious Diseases · 4
PDF
Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)
2022 · Eleftherios Mylonakis, Joseph Lutaakome, et al. · Med · 3
PDF
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial
2022 · Thomas L. Holland, Adit A. Ginde, et al. · SSRN Electronic Journal · 3
The Burden of Non-Communicable Diseases among Hospitalized HIV Positive Patients at Lira Regional Referral Hospital, Northern Uganda: Retrospective Chart Review 2016-2020
2022 · Omech Bernard, Opio Bosco, et al. · Research Square · 2
PDF
Works count: 43
Citation count: 957
H-index: 17
I10-index: 21
Year
Topic
Type